

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

**ADVANCED MEDICAL TECHNOLOGY ASSN**

2. Address:

ADVANCED MEDICAL TECHNOLOGY ASSN, 1200 G ST NW #400, DC 20005

3. Principal place of business (if different from line 2):

Country: City: State/Zip(or Country):

4. Contact Name: MEGAN M. IVORY

Telephone: (202) 783-8700

E-mail (optional): mivory@advamed.org

Senate ID #: 17831-12

House ID #: 31001000

7. Client Name: ☒ Self

## TYPE OF REPORT

8. Year 2006 Midyear (January 1 - June 30): ☒ **OR** Year End (July 1 - December 31): ☐

9. Check if this filing amends a previously filed version of this report: ☐

10. Check if this is a Termination Report: ☐ => Termination Date: 11. No Lobbying Activity: ☐

## INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

### 12. Lobbying Firms

**INCOME** relating to lobbying activities for this reporting period was:

Less than \$10,000: ☐

\$10,000 or more: ☒ => Income (nearest \$20,000): 2,064,087.00

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

### 13. Organizations

**EXPENSES** relating to lobbying activities for this reporting period were:

Less than \$10,000: ☐

\$10,000 or more: ☐ => Expenses (nearest \$20,000): \_\_\_\_\_

### 14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

- ☐ **Method A.** Reporting amounts using LDA definitions only  
☐ **Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code  
☐ **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

Registrant Name: ADVANCED MEDICAL TECHNOLOGY ASSN Client Name: Self

### LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: BUD (one per page)

16. Specific lobbying issues:

H.R. 5384-Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Acts, 2007. (Bill making appropriations for the fiscal year ending September 30, 2007.)

17. House(s) of Congress and Federal agencies contacted:

US HOUSE OF REPRESENTATIVES  
US SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: IVORY, MEGAN  
Covered Official Position (if applicable):  
Name: RADUS, SETH  
Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

## LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

H.R. 2090-Food and Drug Administration Improvement Act of 2005. (Bill related to FDA Advisory panels.) Senate draft bill: Enhancing Drug Safety and Innovation Act of 2006. (Draft bill to improve oversight as related to drugs. Includes medical devices in some provisions.) Senate draft bill: Pediatric Medical Devices. (Draft bill to improve the process for development of needed pediatric medical devices.) Senate draft bill: Small Business Reauthorization and Improvements Act of 2006. H.R. 5352-Small Business Reauthorization Act of 2006. (The draft bill above and this bill relate to reauthorization programs to assist small business concerns.) S. 1263-Save American's Biotechnology Innovative Research Act of 2005. H.R. 2943-Save Biotechnology Innovative Research Act of 2005. (Both bills to establish eligibility requirements for business concerns to receive awards under the Small Business Innovative Research program.) Division E-Public Readiness and Emergency Preparedness Act. (Division E provisions of the bill as related to targeted liability for pandemic and epidemic products and security countermeasures.) S. 2564/H.R. 5533-Biodefense and Pandemic Vaccine and Drug Development Act of 2006. S. 1873-Biodefense and Pandemic Vaccine and Drug Development Act of 2005. S. 1880-National Biodefense and Pandemic Preparedness Act of 2005. (Bills to prepare, enhance and strengthen the development of countermeasures or pandemic or epidemic products against deliberate, accidental, and natural outbreaks of illness.) S. 2972-Emergency Preparedness and Response Security, Accountability, and Flexibility Enhancement Act (SAFE Act.) (Bill to revise provisions relating to bioterrorism and other public health emergencies, preparedness grants including development of measurable critical benchmarks and performance standards.) S. 3-Protecting America in the War on Terror Act of 2005. (Bill sets provisions concerning bioterrorism preparedness and defense as pertaining to medical devices.) S. 975-The Project Bioshield II Act of 2005. (Bill to provide incentives to increase research by private sector entities to develop medical countermeasures to prevent, detect, identify, contain, and treat illnesses, including those associated with biological, chemical, nuclear, or radiological weapons attack or an infectious disease outbreak.) S. 22/S. 23-Malpractice Liability Reform Bill (a.k.a. Medical Care Access Protection Act of 2006, MCAP Act.) Bills setting forth provisions regulating lawsuits for health care liability claims related to the provision of health care services.) H.R. 5-Help Efficient, Accessible, Low-Cost, Timely Healthcare (HEALTH) Act of 2005. (Bill to provide improved medical care by reducing the excessive burden the liability system places on the health care delivery system.) S. Cong. Res. 67/H. Cong. Res. 311-Concurrent resolution urging Japan to honor its commitments under the 1986 Market-Oriented Sector-Selective (MOSS) Agreement on Medical Equipment and for other purposes. (Congressional Resolutions to reduce regulatory barriers to the approval and adoption of new medical technologies.) S. 2467-United States Trade Enhancement Act of 2006. (Bill on trade enforcement efforts as related to trade with China.) S. 295-To authorize appropriate action if the negotiations with the People's Republic of China's undervalued currency are not successful. (Bill to impose an additional duty of 27.5% on Chinese imports.) H.R. 3004-Currency Harmonization Initiative through Neutralizing Action Act of 2005. (Bill to impose additional tariffs on Chinese imports on the basis of the rate of manipulation by that country of the rate of exchange between the Chinese currency and the U.S. dollar.) H.R. 3283/S. 1421-United States Trade Rights Enhancement Act. (Bills to enhance resources to enforce U.S. trade rights.) H.R. 4157-Health Information Technology Promotion Act of 2005. ((Bill to provide for establishment of uniform confidentiality and security standards with respect to individually identifiable patient health information.) S. 1355-Better Healthcare Through Information Technology Act. S. 1418-Wired for Health Care Quality Act. ((Bills to enhance the adoption of health information technology and to improve the quality and reduce the cost of healthcare in the United States.) S. 1952-Critical Access to Health Information Technology Act of 2005. ((Bill to provide for grants to states to increase access to health care in rural areas by improving health information technology.) S. 1223-Information Technology for Health Care Quality and Improvement Act. ((Bill to improve the quality and efficiency of health care delivery through improvements in health care information technology.) S. 1262-Health Technology to Enhance Quality Act of 2005. ((Bill to reduce healthcare costs, improve efficiency and healthcare quality through the development of a nation-wide interoperable health information technology system.) S. 2109-National Innovation Act of 2005. ((Bill to promote research investment, increase science and technology talent, and develop an innovation infrastructure.) S. 950-Elimination of Neglected Diseases Act of 2005. ((Bill to provide assistance to combat tuberculosis, malaria and other infectious diseases.) H.R. 5115-U.S. Healthcare Technologies Competitiveness Act of 2006. ((Bill to modernize the tax treatment as related to medical devices and biomedical research corporations.) H.R. 4845-Innovation and Competitiveness Act. H.R. 1736/S. 627-Investment in America Act of 2005. (Bills to make permanent the tax credit for increasing research activities.) H.R. 4297-Tax Relief Extension Reconciliation Act of 2005. (Bill to extend credit for increasing research activities.) S. 978-Healthcare Tax Relief for the Uninsured Act of 2005. H.R. 1872-Health Coverage for the Uninsured Act of 2005. (Bills to provide tax incentives for the purchase of quality health care, and for other purposes.)

17. House(s) of Congress and Federal agencies contacted:  
Food and Drug Administration  
U.S. Department of Health and Human Services  
US HOUSE OF REPRESENTATIVES  
US SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: IVORY, MEGAN  
Covered Official Position (if applicable):

Registrant Name: ADVANCED MEDICAL TECHNOLOGY ASSN Client Name: Self

Name: SETH, RADUS  
Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: ADVANCED MEDICAL TECHNOLOGY ASSN Client Name: Self

## LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

H.R. 5369-Medicare Clinical Laboratory Fee Schedule Improvement Act of 2006. (Bill to improve payments under the Medical clinical laboratory fee schedule.) S. 1932/H.R. 4241-Deficit Reduction Act of 2005. (Bills concerned with gainsharing and its implications on patient access to medical devices efficiency standards in pay-for-performance program.) H.R. 4297-Tax Relief Extension Reconciliation Act of 2005. S. 2020-Tax Relief Act of 2005. ((Bills to provide for reconciliation pursuant to section 202(b) of the concurrent resolution on the budget for fiscal year 2006.) H.R. 3617-Medicare Value-Based Purchasing for Physicians Services Act of 2005. (Bill to provide for value-based purchasing in the payment for physicians services under the Medicare program.) S. 1356-Medicare Value Purchasing Act of 2005. (Bill to provide incentives for the provision of high quality care under the Medicare program.) S. 1002-Hospital Fair Competition Act of 2005. (Bill to make improvements in payments to hospitals under the Medicare program.) S. 2022-Remote Monitoring Access Act of 2005. (Bill to provide for coverage of remote patient management services for chronic health care conditions under the Medicare program.) H.R. 3559-Medicare Durable Medical Equipment Access Act of 2005. (Bill to assure access to durable medical equipment under the Medicare program.) H.R. 3196/S. 470-Fair Access to Clinical Trials (FACT) Act. (Bills to expand the scope of information required for the data bank on clinical trials.)

17. House(s) of Congress and Federal agencies contacted:  
U.S. Department of Health and Human Services  
US HOUSE OF REPRESENTATIVES  
US SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: IVORY, MEGAN  
Covered Official Position (if applicable):  
Name: RADUS, SETH  
Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Signature: ON FILE Date: Aug 11, 2006

Printed Name and Title: MEGAN M. IVORY, EXECUTIVE VICE PRESIDENT, FEDERAL -

**Information Update Page:**

**Complete ONLY where registration information has changed.**

**21. Client new principal place of business (if different from line 20):**

Country: USA

**LOBBYIST UPDATE**

**23. Name of each previously reported individual who is NO LONGER expected to act as a lobbyist for the client**

Name: Childs, Blair

**ISSUE UPDATE**

**24. General lobbying issues previously reported that NO LONGER pertain**

**AFFILIATED ORGANIZATIONS**

**25. Add the following organization(s)**

**26. Name of each previously reported organization that is NO LONGER affiliated with the registrant or client**

**FOREIGN ENTITIES**

**27. Add the following foreign entities**

**28. Name of each previously reported foreign entity the NO LONGER owns, OR controls, OR is affiliated with the registrant, client or affiliated organization**

Signature: ON FILE Date: Aug 11, 2006

Printed Name and Title: MEGAN M. IVORY, EXECUTIVE VICE PRESIDENT, FEDERAL -